Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2010
01/13/2010CN100579527C Compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes and use method thereof
01/13/2010CN100579526C Compound sustained-release pellet tablet containing nifedipine and atenolol and preparation thereof
01/13/2010CN100579525C Sustained release preparation of licardipine hydrochloride and its preparing process
01/13/2010CN100579524C Method of preparing simvastatin sustained-release microsphere carried series
01/13/2010CN100579523C Dihydroartemisinin emulsion for injection, freeze-dried emulsion and preparation method thereof
01/13/2010CN100579522C Pasting agent
01/13/2010CN100579521C Fatty acid analogues for the treatment of proliferative skin disorders
01/13/2010CN100579520C Slimming appetising capsule containing natural capsicine for promoting blood circulation and reducing blood fat
01/13/2010CN100579519C Use of patchouli alcohol in preparing medicament for preventing and controlling senile dementia
01/13/2010CN100579518C Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
01/13/2010CN100579516C Vaginal effervescence tablet composition containing solid lipid
01/13/2010CN100579513C Preparation method of lung targeting emodin polylactic acid microsphere
01/13/2010CN100579512C Method of producing water-solubility hypocrellin titanium dioxide nano granule
01/13/2010CN100579511C Ratification of highly purified tranexamic acid injection and quality standard thereof
01/13/2010CN100579510C Precursor micelle preparation and its production process
01/13/2010CN100579508C Oral-cleaning orally disintegrating tablet and preparing technique thereof
01/13/2010CN100579373C Compositions containing opioid antagonists
01/12/2010US7645903 immunoglobulins; affinity chromatography
01/12/2010US7645898 Selective androgen receptor modulators and method of use thereof
01/12/2010US7645887 Indolone-acetamide derivatives, processes for preparing them and their uses
01/12/2010US7645885 (E)-Methyl 3-(1,2,3,4,8,8 alpha -hexahydro-8 alpha -methylspiro[1',3'-dithiolane-2',6(7H)naphthalen]-1-yl)acrylate; for treating or preventing diseases ( prostate cancer, benign prostatic hyperplasia, reproductive disorders, and male hypogonadism) associated with androgen binding to the androgen receptor
01/12/2010US7645873 6-azido-2,3,4-tetra-O-benzyl-6-deoxymethylgalactopyranoside ; for treating cancer or autoimmune disorders
01/12/2010US7645871 Tumor inhibition by modulating sprouty expression of activity
01/12/2010US7645870 Short interfering RNA sequences for use as therapeutic tools in treatment of cancer, diabetes and nervous system disorders
01/12/2010US7645869 Short interference RNA duplexes when introduced into mammalian cells in culture perform sequence-specific inhibition of target mRNA without inducing an interferon response; for gene silencing to treat human diseases; double stranded siRNA
01/12/2010US7645864 N-demethyl-N-isopropyl-12-methoxy-11-oxo-8,9-anhydroerythromyc in A-6,9-hemiacetal fumarate; treating with ethyl acetate; reduced content of residual solvent and high suitability for formulation
01/12/2010US7645863 Adding a second organic solvent to a concentrated moxidectin solution to obtain a weight ratio of 2:I to 6:I with respect to the first solvent; cooling and recovering crystals of 94-96% purity being 2-5% purer than the amorphous form; veterinary medicine; antithelmintics; parasiticides
01/12/2010US7645816 Water-soluble compositions of bioactive lipophilic compounds
01/12/2010US7645803 containing a saccharide for use in the treatment of dermal disorders including H2O; a saccharide; a nonionic surfactant such as polyoxyethylene glycol sorbitan monostearate, a polymeric agent selected from a bio-adhesive agent, gelling agent; film forming agent; phase change agent; adjuvant; propellant
01/12/2010US7645802 Controlled release, once daily formulation; reducing seizure side effects; antidepressant
01/12/2010US7645800 17-phenyl trinor PGF2 alpha cyclopropylmethyl amide, for example; stimulates hair growth of scalp, eyebrows or eyelashes or restores hair color to depigmented hair
01/12/2010US7645799 thromboembolic and/or inflammatory disorders; 4-Aminomethyl-cyclohexanecarboxylic acid (1-biphenyl-3-yl-2-phenyl-ethyl)-amide; selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; improved pharmacological properties, plasma kallikrein activity
01/12/2010US7645798 N-(2-hydroxyalkanoyl)-N,N′-dialkylureas and a process for their preparation
01/12/2010US7645797 Gamma aminobutyric acid antagonist such as naphthylalanine; antiepileptic agents; antidepressants; anxiolytic agents; psychological disorders; neurodegenerative diseases; analgesics; drug withdrawal
01/12/2010US7645796 Amino acid composition promoting collagen synthesis
01/12/2010US7645795 Administering a nutritional supplement phosphatidylcholine, linoleic acid and alpha linoleic acid in combination with mineral; inhibit the disease progression or delay the symptoms; using nutraceuticals to treat neurodegenerative diseases
01/12/2010US7645794 containing ethyl pyruvate and a therapeutically effective amount of at least one alpha -hydroxy branched-chain amino acid metabolite selected from alpha-hydroxyisocaproic acid, alpha -hydroxy- beta -methylvaleric acid, and alpha -hydroxy-isovaleric acid; time-release agents; nutritional supplement
01/12/2010US7645793 Effective ingredient and basic agent; foam suppression
01/12/2010US7645791 5-tert-Butyl-4-hydroxy-2-methyl-biphenyl-3-carboxylic acid (2-chloro-4-nitro-phenyl) -amide; chemical uncouplers like for the treatment of obesity
01/12/2010US7645790 Hydroisoindoline tachykinin receptor antagonists
01/12/2010US7645789 Modulators of ATP-Binding Cassette transporters; Cystic Fibrosis Transmembrane Conductance Regulator; N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide
01/12/2010US7645788 Treating breast cancer cells which are both estrogen-dependent and estrogen-negative; chemical systhesis by reacting indole-3-carbinol with an oxidizing agent in a solvent, cyclization, purification
01/12/2010US7645787 4'-((2-fluoro-4-methylphenyl)methyl)-1'-isopropyl-5'-methyl-1H-pyrazole-3'-O-(6-carbomethoxy)- beta -D-glucopyranoside; 4-[(3-fluoro-4-methoxyphenyl)methyl]-1-isopropyl-5-methyl-1H-pyrazole-3-O- beta -D-glucopyranoside; reducing reanal glucose reabsorption
01/12/2010US7645786 Substituted arylpyrazoles
01/12/2010US7645785 Farnesoid-X-receptors (FXR) agonists; diabetes and dyslipidemia; 2,N-dicyclohexyl-2-(2-phenyl-benzoimidazol-1-yl)-acetamide hydrogen chloride
01/12/2010US7645784 Benzimidazole derivatives
01/12/2010US7645783 Halogenated benzamide derivatives
01/12/2010US7645782 Ethyl (2Z,5S,6E)-5-(tert-Butyl-dimethyl-silanyloxy)-2,6-dimethyl-7-(2-methyl-1,3-thiazol-4-yl)-hepta-2,6-dienoate; (3S)-3-(tert-Butyl-dimethyl-silanyloxy)-tetrahydrofuranone; breast , epidermoid, ovarian, lung, prostate cancer, cervix carcinoma, cancer of the bladder or leukemia
01/12/2010US7645781 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives
01/12/2010US7645780 N-[(1S,2R)-3-{[1-(3-bromophenyl)cyclopropyl]amino}-1-(3,5-difluorobenzyl)-2-hydroxypropyl]acetamide hydrochloride; for Alzheimer's disease; inhibitors of beta-secretase
01/12/2010US7645779 Linked biaryl compounds
01/12/2010US7645778 Heteroaryl compounds as P2Y1 receptor inhibitors
01/12/2010US7645777 Switching device
01/12/2010US7645776 (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia
01/12/2010US7645775 N3-[4-(4-Morpholin-4-yl-cyclohexyl)-phenyl]-1-pyridin-2-yl-1H-[1,2,4]triazole-3,5-diamine; antiproliferative agent; Alzheimer's Disease; Multiple Sclerosis Parkinson's Disease, asthma, schizophrenia, anti-nflammatory agent; cardiovascular disease; bone disorders
01/12/2010US7645774 Sulfonamide-containing benzene derivatives; cancer and inflammatory, immunomodulatory or respiratory diseases; allergy, seasonal allergic rhinitis, reversible airway obstruction, adult respiratory distress syndrome, asthma, or bronchitis
01/12/2010US7645773 Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
01/12/2010US7645772 Treatment of metabolic disorders
01/12/2010US7645771 HIV, acquired immune deficiency syndrome (AIDS); 1-(8-{2-[1-(2,2-Dimethylpropanoyl)-4-phenylpiperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole
01/12/2010US7645770 Phenylalanine enamide derivatives
01/12/2010US7645769 Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation
01/12/2010US7645768 Production of polyketides and other natural products
01/12/2010US7645767 Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
01/12/2010US7645766 Method for treatment of depression and depressive mood disorders
01/12/2010US7645765 With water miscible solubilizer; phosphodiesterase inhibitors; cardiovascular disorders
01/12/2010US7645764 Kinase inhibitors and methods for using the same
01/12/2010US7645763 dipeptidylpeptidase-IV inhibitors; antidiabetic agents, antiarthritic agents, obesity, allograft transplantation, and osteoporosis caused by calcitonin; 1,3-disubstituted-7-(2-butyn-1-yl)-8-(3-aminopiperidin-1-yl)-xanthine compounds
01/12/2010US7645762 Substituted pyrazolo[1,5-a] pyrimidines as protein kinase inhibitors
01/12/2010US7645761 Indoline derivatives
01/12/2010US7645760 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
01/12/2010US7645759 (4-(S)-amino-5-(4-{4-[2,4-dichloro-3-(2,4-dimethyl-quinolin8yloxy-methyl) benzenesulfonylamino] tetrahydropyran-4carbonyl}-piperazin-1-yl)-5-oxo-pentyl] trimethyl-ammonium chloride, dihydrochloride; asthma or chronic bronchitis
01/12/2010US7645758 (4-Methyl-piperazin-1-yl)-(6H-thieno[2,3-b]pyrrol-5-yl)-methanone; (2,3-Dichloro-6H-thieno[2,3-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone; histamine H4 receptor antagonist; treats allergic rhinitis
01/12/2010US7645757 Derivatives of heteroaryl-alkylcarbamates, methods for their preparation and use thereof as fatty acid amido hydrolase enzyme inhibitors
01/12/2010US7645756 Nitrogenous fused heteroaromatic ring derivative
01/12/2010US7645755 5-Cyano-1H-imidazole-2-carboxylic acid [4-(3,6-dihydro-2H-pyran-4-yl)-2-(4,4-dimethyl-cyclohex-1-enyl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent
01/12/2010US7645754 Pyrrolopyrimidine A2B selective antagonist compounds, their synthesis and use
01/12/2010US7645753 Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
01/12/2010US7645752 Inhibitors of norepinephrine reuptake; 5-HT2A receptor inhibitors; N,N-dimethyl-N-{2-[3-(phenylsulfonyl)-1H-indol-5-yl]ethyl}amine; 3-(phenylsulfonyl)-7-(2-pyrrolidin-1-ylethyl)-1H-indole;
01/12/2010US7645751 Mandelic acid derivatives and their use as thrombin inhibitors
01/12/2010US7645750 Using serotonin and/or dopamine type 2 receptor antagonists; peri or post menopause; safe alternative to estrogen replacement therapy
01/12/2010US7645749 contains ester linkage of a nitric oxide (NO)-releasing moiety to a sterol or stanol compound; useful for treating atherosclerosis, hypercholesterolemia, hyperlipidemia, hypertension, thrombosis, Type II diabetes, dementia, Alzheimer's disease and aging
01/12/2010US7645748 include a phosphate linker, at least one nitrate group that releases nitric oxide (NO), and a sterol or stanol group; useful for treating atherosclerosis, hypercholesterolemia, hyperlipidemia, hypertension, thrombosis, Type II diabetes, dementia, Alzheimer's disease and aging
01/12/2010US7645747 Improved pharmacokinetic properties, oral bioavailability; side effect reduction
01/12/2010US7645746 Composition for reducing malodor impression on inanimate surfaces
01/12/2010US7645745 Propionic Acid (2R,3R,4R,5R)-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-4-hydroxy-4-methyl-3-propionyloxy-tetrahydro-furan-2-ylmethyl ester; inhibit RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase
01/12/2010US7645744 Compositions and methods for siRNA inhibition of HIF-1 alpha
01/12/2010US7645743 Administering immunity linkers with more than one binding site, wherein second site binds to target and individual has pre-existing cellular or humoral immune response to first site; high speed response to public health needs such as pandemic infections; biological warfare; vaccines
01/12/2010US7645742 administering a formulation containing creatine, L-arginine- alpha -ketoglutarate, D-ribose, L-carnitine, L-citrulline, and pyruvate to a mammal performing a physical activity 15-30 minutes before initiation of the physical activity; increases endurance and muscle mass of the person
01/12/2010US7645738 18-membered nitrobenzyl- and aminobenzyl-substituted cyclohexadepsipeptides for controlling endoparasites and a process for their preparation
01/12/2010US7645736 injecting an alpha-v. beta 3 or alpha-v, beta 5 inhibitor into the vitreous body of the eye; angiogenesis inhibition; diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid
01/12/2010US7645732 administering antiviral agents, very low density lipoproteins (VLDL) assembly inhibitors, such as small interfering RNA or antisense oligonucleotide directed against apolipoprotein B, or microsomal triglyceride transfer protein (MTP) inhibitors, to inhibit release of HCV from an HCV-infected cells
01/12/2010US7645595 Culturing epidermal keratinocytes on collagen gel layer containing human fibroblasts, exposing to air, and culture contains matrix metalloproteinase inhibitor such as N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride
01/12/2010US7645465 Includes acid-treatment of ginseng and bio-converting treatment, such as lactic acid bacterial fermenting and intestinal bacterial fermenting process, extracting acid treated ginseng with organic solvent to obtain organic extract, fermenting organic extract with lactic-acid bacteria Bifidobacterium KK-1
01/12/2010US7645461 Method of treating cerebral ischemia with hydrogenation products of frankincense extracts
01/12/2010US7645460 Dosage forms of risedronate
01/12/2010US7645459 Oral dosage form having pharmaceutically effective absorption comprising 1-500 mg of a bisphosphonate which is selected from risedronate and acids, salts, and esters thereof, 10-500 mg of EDTA, and a delayed release mechanism to deliver the bisphosphonate and the EDTA in the lower gastrointestinal tract
01/12/2010US7645441 Compositions and methods in cancer associated with altered expression of PRLR
01/12/2010US7645419 Killing microorganisms
01/12/2010CA2573404C Substituted oxindole derivatives and medicaments containing the same
01/12/2010CA2560489C Pyranone compounds useful to treat retroviral infections